Role of Nε-(carboxymethyl)lysine in the development of ischemic heart disease in type 2 diabetes mellitus

Journal of Clinical Biochemistry and Nutrition

Volumn 41, Issue 2, 2007, Pages 97-105

  Ahmed, Khaled A ^a   Muniandy, Sekaran ^a   Ismail, Ikram S ^b  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

Author keywords

Advanced glycation end products; Ischemic heart disease; N (carboxymethyl)lysine; Oxidative stress; Type 2 diabetes mellitus

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYSINE DERIVATIVE; MALONALDEHYDE; N EPSILON (CARBOXYMETHYL)LYSINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOREACTIVITY; ISCHEMIC HEART DISEASE; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PROTEIN ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 34948866656     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.2007014     Document Type: Article

References (48)

1. Schwartz, C.J., Valente, A.J., Sprague, E.A., Kelley, J.L., Cayatte, A.J., and Rozek, M.M.: Pathogenesis of the atherosclerotic lesion: Implications for diabetes mellitus. Diabetes Care, 15, 1156-1160, 1992.
2. Manson, J.E., Colditz, G.A., Stampfer, M.J., Willett, W.C., Krolewski, A.S., Rosner, B., Arky, R.A., Speizer, F.E., and Hennekens, C.H.: A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch. Intern. Med., 151, 1141-1147, 1991.
3. Laakso, M. and Lehto, S.: Epidemiology of macrovascular disease in diabetes. Diabetes Res., 5, 294-315, 1997.
4. Haffner, S.M., Lehto, S., Rönnemaa, T., Pyörälä, K., and Laakso, M.: Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med., 339, 229-234, 1998.
5. Pyörälä, K., Laakso, M., and Uusitupa, M.: Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab. Rev., 3, 463-524, 1987.
6. Gu, K., Cowie, C.C., and Harris, M.I.: Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care, 21, 1138-1145, 1998.
7. Assal, J.P.: Hyperglycemia and diabetic complications. Schweizerische Medizinische Wochenschrift, 109, 1791-1801, 1979.
8. Hudson, B.J., Hofmann, M.A., Bucciarelli, L., Wendt, T., Moser, B., Yan, L., Wu, Q., Stern, D.M., D'Agati, V., Yan, S.D., Yan, S.F., Grant, P.J., and Schmidt, A.M.: Glycation and diabetes: The RAGE connection. Current Science, 83, 1515-1521, 2002.
9. Wautier, J.L. and Guillausseau, P.J.: Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes. Metab., 27, 535-542, 2001.
10. Dyer, D.G.: Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J. Clin. Invest., 91, 2463-2469, 1993.
11. Price, D.L., Rhett, P.M., Thorpe, S.R., and Baynes J.W.: Chelating activity of advanced glycation end-product inhibitors. J. Biol. Chem., 276, 48967-48972, 2001.
12. Monnier, V.M., Kohn, R.R., and Cerami, A.: Accelerated age-related browning of human collagen in diabetes mellitus. Proc. Nat. Acad. Sci. USA, 81, 583-587, 1984.
13. Yan, S.D., Schmidt, A.M., Anderson, G.M., Zhang, J., Brett, J., Zou, Y.S., Pinsky, D., and Stern, D.: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem., 269, 9889-9897, 1994.
14. Baynes, J.W.: Role of oxidative stress in development of complications in diabetes. Diabetes, 40, 405-412, 1991.
15. ε-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J. Biol. Chem., 261, 4889-4894, 1986.
16. ε-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry, 34, 10872-10878, 1995.
17. ε-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem. J., 324, 565-570, 1997.
18. Ienaga, K., Nakamura, K., Hochi, T., Nakazawa, Y., Fukunaga, Y., Kakita, H., and Nakano, K.: Crosslines, fluorophores in the AGE-related crosslinked proteins. Contributions Nephr., 112, 42-51, 1995.
19. Sell, D.R. and Monnier, V.M.: Structure elucidation of a senescence cross-link from human extracellular matrix: Implication of pentoses in the aging process. J. Biol. Chem., 264, 21597-21602, 1989.
20. Njoroge, F.G., Sayre, L.M., and Monnier, V.M.: Detection of glucose-derived pyrrole compounds during Maillard reaction under physiological conditions. Carbohydr. Res., 167, 211-220, 1987.
21. Niwa, T., Katsuzaki, T., Miyazaki, S., Miyazaki, T., Ishizaki, Y., Hayase, F., Tatemichi, N., and Takei, Y.: Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J. Clin. Invest., 99, 1272-1280, 1997.
22. Booth, A., Khalifah, R.G., Todd, P., and Hudson, B.G.: In vitro kenetic studies of formation of antigenic advanced glycation end products (AGEs). J. Biol. Chem., 272, 5430-5437, 1997.
23. ε-(carboxymethyl) lysine in human tissues in diabetes and ageing. J. Clin. Invest., 99, 457-468, 1997.
24. ε-(carboxymethyl) lysine formation from Amadori product. Biochem. Biophys. Res. Comm., 234, 167-172, 1997.
25. ε- (carboxymethyl)lysine is a product of both lipid peroxidation and glycoxidation reactions. J. Biol. Chem., 271, 9982-9986, 1996.
26. ε-(Carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry, 35, 8075-8083, 1996.
27. Ledl, F. and Schleicher, E.: The Maillard reaction in food and in human body, new results in chemistry, biochemistry and medicine. Angew. Chem. Int. Ed. Engl., 29, 565-706, 1999.
28. Maziere, C., Auclair, M., Ronveaux, M.F., Salmon, S., Santus, R., and Maziere, J.C.: Estrogens inhibit copper and cell-mediated modification of low density lipoprotein. Atherosclerosis, 89, 175-182, 1991.
29. Holvoet, P., Stassen, J.M., Cleemput, J.V., Collen, D., and Vanhaecke, J.: Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease. Arterioscler. Thromb. Vasc. Biol., 18, 100-107, 1998.
30. World Health Organization, WHO Study Group on Diabetes Mellitus, Geneva, World Health Org., (Tech. Rep. Ser., no. 727), 1985.
31. Dagenais, G.R., Robitaille, N.M., Lupien, P.J., Christen, A., Gingras, S., Moorjani, S., Meyer, F., and Rochon, J.: First coronary heart disease event rates in relation to major risk factors: Quebec cardiovascular study. Can. J. Cardiol., 6, 274-280, 1990.
32. Lamarche, B., Després, J.P., Moorjani, S., Cantin, B., Dagenais, G.R., and Lupien, P.J.: Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Québec Cardiovascular Study). Am. J. Cardiol., 75, 1189-1195, 1995.
33. Bradford, M.M.: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248-254, 1976.
34. Bjerrum, O.J., Ingild, A., Løwenstein, H., and Weeke, B.: Quantitation of human IgG by rocket immunoelectrophoresis at pH 5 by use of carbamylated antibodies. A routine laboratory method. Clin. Chem. Acta, 46, 337-343. 1973.
35. Habeeb, A.F.: Determination of free amino groups in proteins by trinitrobenzene-sulfonic acid. Anal. Biochem., 14, 328-336, 1966.
36. ε-(carboxymethyl) lysine in rat serum and urine proteins with aging: Link with glycoxidative damage accumulation in kidney. Arch. Biochem. Biophys., 411, 215-222, 2003.
37. Makita, Z., Vlassara, H., Cerami, A., and Bucala, R.: Immunochemical detection of advanced glycosylation end products in vivo. J. Biol. Chem., 267, 5133-5138, 1992.
38. Ohkawa, H., Ohishi, N., and Yagi, K.: Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem., 95, 351-358, 1979.
39. Tsaknis, J, Lalas, S., Tychopoulos, V., Hole, M., and Smith, G.: Rapid high-performance liquid chromatographic method of determining malondialdehyde for evaluation of rancidity in edible oils. Analyst, 123, 325-327, 1998.
40. rd Ed., pp. 163-172, 1983.
41. Friedewald, W.T., Levy, R.I., and Fredrickson, D.S.: Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clinic. Chem., 18, 499-502, 1972.
42. Bierman, E.L.: George lyman duff memorial lecture: atherogenesis in diabetes. Arterioscler. Thromb. Vasc. Biol., 12, 647-656, 1992.
43. Nesto, R.W.: Screening for asymptomatic coronary artery disease in diabetes. Diabetes Care, 22, 1393-1395, 1999.
44. Paillole, C., Ruiz, J., Juliard, J.M., Leblanc, H., Gourgon, R., and Passa, P.: Detection of coronary artery disease in diabetic patients. Diabetologia, 38, 726-731, 1995.
45. Kilhovd, B.K., Berg, T.J., Birkeland, K.I., Thorsby, P., and Hanssen, K.F.: Serum levels of advanced glycation end products are increased in patients with Type 2 diabetes and coronary heart disease. Diabetes Care, 22, 1543-1548, 1999.
46. Kiuchi, K., Nejima, J., Takano, T., Ohta, M., and Hashimoto, H.: Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in Type 2 diabetic patients. Heart, 85, 87-91, 2001.
47. Tanaga, K., Bujo, H., Inoue, M., Mikami, K., Kotani, K., Takahashi, K., Kanno, T., and Saito, Y.: Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles. Arterioscler. Thromb. Vasc. Biol., 22, 662-666, 2002.
48. Imanaga, Y., Sakata, N., Takebayashi, S., Matsunaga, A., Sasaki, J., Arakawa, K., Nagai, R., Horiuchi, S., Itabe, H., and Takano, T.: In vivo and in vitro evidence for the glycoxidation of low density lipoprotein in human atherosclerotic plaques. Atherosclerosis, 150, 343-355, 2000.